Podcast

Epigenomic Programming With Omega Therapeutics' Mahesh Karande

Source: Cytiva
22_01_bpo_busbiotech_social_ep115

Using computational biology to hasten the effort, Omega Therapeutics' plan is to "coopt nature's universal biological operating system for gene control and cell differentiation." On this episode of the Business of Biotech, we dig into exactly what that means. We also explore the company's preclinical ambitions, which are diverse, targeting regenerative, multigenic/immunologic, oncologic, and monogenic indications. Omega is leaning heavily into computational biology along the way, having mapped what CEO Mahesh Karande characterizes as 95% of the IDG landscape. Learn how Karande intends to maintain momentum on this episode of the Business of Biotech. 

          

 

 

LISTEN TO THE PODCAST!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Laboratory Network? Subscribe today.

Subscribe to Laboratory Network X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Laboratory Network